Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Octagon Capital Advisors reduced its stake in Dianthus Therapeutics by 470,000 shares, valued at $27.22 million, according to a May 15, 2026 SEC filing. Despite the sale, Dianthus remains Octagon's largest disclosed position, indicating continued bullishness on the company's long-term autoimmune pipeline. Dianthus Therapeutics, a clinical-stage biotechnology company, has seen its shares increase by about 320% over the last year and has significant cash reserves to fund its operations into 2030, with key clinical trials progressing.
RA Capital group reports 2,611,733 Dianthus shares (DNTH)
RA Capital Management, L.P., along with other reporting persons, has disclosed a beneficial ownership of 2,611,733 shares of Dianthus Therapeutics, Inc. (DNTH) common stock, representing 4.8% of the outstanding shares as of March 31, 2026. The filing, a SCHEDULE 13G/A amendment, states that RA Capital has been delegated sole voting and dispositive power over these shares, while expressly disclaiming group status and beneficial ownership beyond Section 13(d) obligations. The report provides detailed figures on shareholdings, percentage of class, and outstanding shares, and clarifies the governance structure regarding the delegated powers.
Point72 reports 643,599 shares (1.2%) in Dianthus Therapeutics (DNTH)
Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc., and Steven A. Cohen, has filed an Amendment No. 2 to a Schedule 13G/A, reporting a 1.2% beneficial ownership stake in Dianthus Therapeutics (DNTH). As of March 31, 2026, they beneficially owned 643,599 shares of Common Stock. This stake is held through an investment fund managed by Point72, with shared voting and dispositive power.
Sirenia Capital (DNTH) discloses 5.3% stake including 500K options
Sirenia Capital Management and Alex Silverstein have disclosed a 5.3% passive stake in Dianthus Therapeutics (DNTH) through a joint Schedule 13G filing. This ownership amounts to 2,798,122 shares, which includes 500,000 shares issuable upon the exercise of call options. The calculation for the percentage is based on an aggregate of 52,942,083 outstanding shares of Dianthus Therapeutics.
Wellington group reports 4.77% stake in Dianthus (NASDAQ: DNTH)
Wellington Management Group LLP and related entities have filed a Schedule 13G/A, disclosing a 4.77% beneficial ownership stake in Dianthus Therapeutics, Inc. (NASDAQ: DNTH). This represents 2,595,783 shares of common stock, with shared voting power over 2,358,243 shares and shared dispositive power over all beneficially owned shares. The filing indicates a passive investment posture across Wellington affiliates, with ownership held by clients via investment advisers.
Octagon entities disclose 1.95M-share stake in Dianthus Therapeutics (DNTH)
Octagon-affiliated entities have reported a 1.95 million-share stake in Dianthus Therapeutics (DNTH), representing 3.6% of the company's common stock. This update comes via an Amendment No. 3 to a Schedule 13G/A filing, indicating shared voting and dispositive power over these shares. The ownership structure includes Octagon Investments Master Fund LP and Octagon Biotech Opportunities Fund I LP, with Ting Jia identified as the controlling person of Octagon.
Vanguard Group Inc. Increases Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
Vanguard Group Inc. significantly increased its stake in Dianthus Therapeutics, Inc. by 24.7% in the fourth quarter, bringing its total holdings to approximately 2.05 million shares valued at $84.4 million. Several other institutional investors also raised their positions, with hedge funds and institutions now owning 47.53% of the company despite recent insider selling. Analysts maintain a positive outlook for Dianthus Therapeutics, with multiple "buy" or "overweight" ratings and price targets reaching up to $135.
Should Dianthus Therapeutics’ (DNTH) Big Cash Raise and LBL-047 Bet Prompt Investor Reassessment?
Dianthus Therapeutics recently announced a significant upsized public offering, raising approximately US$719 million, and selected Sjögren's disease, systemic lupus erythematosus, and dermatomyositis as priority indications for its LBL-047 program. This move expands the company's cash runway to around US$1.11 billion and diversifies its autoimmune portfolio. Despite a wider first-quarter net loss, the focus on LBL-047's dual-mechanism potential, alongside existing late-stage programs, sharpens the near-term catalyst map for investors, emphasizing a high-risk, platform-style autoimmune investment.
Dianthus Therapeutics (DNTH) director exercises options, sells 599 shares under 10b5-1 plan
Dianthus Therapeutics director Paula Soteropoulos exercised options to acquire 599 shares at $8.44 per share and subsequently sold those 599 shares at $85.47 per share on May 8, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on December 23, 2025. The Form 4 filing details the exercise of a stock option with an expiration date of June 6, 2032, and the vesting schedule of the underlying shares.
UBS Group AG Acquires 469,547 Shares of Dianthus Therapeutics, Inc. $DNTH
UBS Group AG significantly increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) during the fourth quarter, adding 469,547 shares to reach a total of 606,620 shares valued at approximately $25 million. Analysts maintain a largely bullish outlook with a consensus "Buy" rating and an average price target of $117.82, despite the company remaining unprofitable with an EPS of -$0.85 against an estimated -$1.07. Insider selling also occurred during the same quarter, with executives liquidating a substantial number of shares.
Number of shareholders of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This page from TradingView provides financial information for Dianthus Therapeutics, Inc. (NASDAQ: DNTH), specifically focusing on the number of shareholders. It allows users to view data related to this metric over different periods, though explicit values are not displayed in the provided content. The page also mentions various data providers and copyright notices.
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded Dianthus Therapeutics (NASDAQ:DNTH) from a "sell" to a "hold" rating, contributing to a generally positive analyst outlook for the stock. The company's recent quarterly earnings surpassed expectations, with EPS of -$0.85 and revenue of $0.46 million both beating forecasts. Dianthus Therapeutics currently holds an average "Buy" rating from analysts with a consensus price target of $117.82.
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: 47.87% Potential Upside in the Biotech Arena
Dianthus Therapeutics (DNTH) is a clinical-stage biotech company focusing on therapies for severe autoimmune diseases. Despite a recent stock dip and current unprofitability, analysts project a 47.87% potential upside due to its innovative pipeline, including claseprubart and DNTH212. The company, with a $4.67 billion market cap, is heavily investing in R&D, showing strong long-term growth potential amidst short-term volatility and financial challenges.
Raymond James Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $125
Raymond James has reiterated its "Buy" rating for Dianthus Therapeutics (DNTH.US) and increased its price target for the stock to $125. This adjustment reflects the firm's continued confidence in the company's prospects.
Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $110
Truist Financial has reiterated its Buy rating on Dianthus Therapeutics (DNTH.US) and set a price target of $110. This indicates an optimistic outlook from the firm regarding the company's future stock performance.
Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates
Dianthus Therapeutics, Inc. (DNTH) announced a Q1 loss, missing revenue estimates. The company reported a net loss of $0.62 per share, which was worse than the analyst consensus of a $0.57 loss per share. Revenue for the quarter was $0, falling short of the $130,000 estimate.
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS
Dianthus Therapeutics (NASDAQ:DNTH) reported earnings results, beating analyst expectations with an EPS of ($0.85) against a consensus of ($1.10), and revenue of $0.46 million compared to an estimated $0.40 million. Despite the beat, the company remains unprofitable with large negative margins. The stock price rose to $90.24, and Wall Street maintains a largely positive outlook with a consensus "Buy" rating, although significant insider selling has occurred recently.
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q1 Revenue $463K, vs. FactSet Est of $404K
Dianthus Therapeutics, Inc. (DNTH) reported first-quarter revenue of $463,000, surpassing the FactSet estimate of $404,000. The company is a clinical-stage biotechnology firm focused on developing antibody complement therapeutics for severe autoimmune diseases. Its flagship product candidate, DNTH103, is currently in a Phase 2 trial for generalized Myasthenia Gravis and is planned for additional trials in other neuromuscular conditions.
Dianthus (Nasdaq: DNTH) raises $719M, ends Q1 2026 with $1.2B cash
Dianthus Therapeutics reported a Q1 2026 net loss of $40.8 million ($0.85 per share) but ended the quarter with a robust $1.2 billion in cash, cash equivalents, and investments. This strong cash position, largely due to a $719 million public offering, is expected to fund operations into 2030, supporting its autoimmune disease pipeline, including advancements in claseprubart and the selection of initial indications for DNTH212. The company highlighted progress in its clinical trials, including an early "GO" decision for the CAPTIVATE CIDP trial and Orphan Drug Designation for claseprubart in Myasthenia Gravis.
Dianthus Q1 Loss Widens, Cash Runway to 2030 | DNTH Stock News
Dianthus Therapeutics (NASDAQ: DNTH) reported its Q1 2026 financial results, revealing a widened net loss of $40.8 million ($0.85 per share) compared to Q1 2025. Despite the increased loss and rising R&D and G&A expenses, the company announced significant progress in its clinical programs, including an early "GO" decision in its CAPTIVATE CIDP trial after 20 confirmed responders and FDA Orphan Drug Designation for claseprubart in Myasthenia Gravis. A successful public offering raised approximately $719 million, extending the company's cash runway to an estimated $1.2 billion, projected to last into 2030.
Dianthus Therapeutics (DNTH) to Release Earnings on Monday
Dianthus Therapeutics (DNTH) is scheduled to release its Q1 2026 earnings after market close on Monday, May 11th, with analysts forecasting an EPS of ($1.1029) and revenue of $0.404 million. Despite recent insider selling, the stock rose 3.6% to $90.58, and several firms have raised price targets, maintaining a consensus "Buy" rating with an average target of $115.55. The company, a clinical-stage biotech developing DNTH103 for autoimmune diseases, also reported institutional activity with varying changes in holdings.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics granted equity awards to six new non-executive employees on May 1, 2026. These inducement grants, approved by the company's Compensation Committee, consist of non-qualified stock options for 135,000 shares of common stock with a 10-year term and an exercise price of $87.42 per share. The grants aim to attract new talent and are in accordance with Nasdaq Listing Rule 5635(c)(4).
Six new Dianthus hires get options to buy 135,000 shares
Dianthus Therapeutics granted inducement equity awards to six new non-executive employees on May 1, 2026, totaling 135,000 non-qualified stock options. These options have a 10-year term, an exercise price of $87.42 per share, and vest over four years. This move is part of the company's ongoing hiring efforts and follows recent significant financial activities.
Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6%
Dianthus Therapeutics (NASDAQ:DNTH) experienced a 27.6% decrease in short interest, totaling 6,564,599 shares as of April 15th, representing 13.1% of its float. Despite missing earnings estimates with a ($1.43) EPS loss, analysts maintain a broadly bullish outlook with a consensus price target of $115.55 and mostly "Buy" or "Outperform" ratings. However, insiders have sold a significant amount of stock, valued at approximately $26.6 million, over the last 90 days.
BlackRock holds 2.63M Dianthus shares (NASDAQ: DNTH) — 5.1% stake
BlackRock, Inc. has reported a beneficial ownership of 2,634,004 shares of Dianthus Therapeutics Common Stock, which constitutes a 5.1% stake in the company. This disclosure, made via a Schedule 13G SEC filing, indicates BlackRock holds sole voting power for 2,582,959 shares and sole dispositive power for all 2,634,004 shares. The filing, dated April 27, 2026, attributes these holdings to various Reporting Business Units of BlackRock.
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Eases Claseprubart Trial Requirements
Dianthus Therapeutics (DNTH) is under scrutiny after the FDA eased trial requirements for its drug claseprubart, leading to varied stock performance but significant long-term momentum. The company is currently valued at approximately US$4.8 billion and trades at a price-to-book multiple of 9.6x, indicating it is overvalued compared to the broader US biotech industry average. Investors are advised to consider the potential for rapid change based on future data or capital needs, given the company's low revenue and substantial net loss.
Does Dianthus Therapeutics (DNTH) Trial Easing Quietly Redefine Its Long-Term Neuromuscular Strategy?
Dianthus Therapeutics recently announced that the FDA removed certain antinuclear antibody screening and testing requirements for its claseprubart clinical trials, following a safety review. This regulatory easing, coupled with an analyst's reaffirmed "Outperform" rating, suggests increasing confidence in the drug's development. While it may smooth patient enrollment for future studies, the company's investment narrative still hinges on upcoming clinical trial readouts for other conditions and its ability to overcome financial risks like significant cash burn and equity dilution.
Dianthus rises as FDA agrees with proposed changes to lead program
Dianthus Global (DNTH) shares rose after the FDA agreed to proposed changes for its lead program, DNTH103, for generalized Myasthenia Gravis. The FDA concurred with the company's plan for a single Phase 3 registrational trial and the use of the MG-ADL scale as the primary endpoint.
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength?
This article examines the recent performance of Dianthus Therapeutics, Inc. (DNTH), which saw its stock price increase by 5.6%. It questions whether this rise indicates a continued strengthening trend for the company's shares.
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier
Dianthus Therapeutics Inc (NASDAQ: DNTH) has received favorable news from the FDA regarding its claseprubart clinical trials, as the regulator has dropped certain screening and testing requirements. This change is expected to ease patient enrollment and may positively impact the drug's labeling. William Blair maintains an Outperform rating on DNTH, citing strong interim results from the CAPTIVATE trial and the potential for claseprubart to treat autoimmune disorders, with key trial results expected in mid-2026 and 2028.
Dianthus Therapeutics CFO Sells All Shares in 2026 Transaction | Company Update - News and Statistics
Ryan Savitz, CFO and Chief Business Officer of Dianthus Therapeutics, has sold his entire direct holding of 8,224 company shares for approximately $739,000. This transaction was part of a pre-arranged trading plan established in December 2025. Following the sale, Savitz no longer directly owns common stock but retains a substantial 71,776 stock options.
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Dianthus Therapeutics' CFO, Ryan Savitz, sold 8,224 shares for $739,000 through an option exercise and immediate sale under a Rule 10b5-1 plan. This transaction, which reduced his direct ownership to zero, is characterized as routine liquidity management rather than a strategic shift. Despite the sale, Savitz retains options for 71,776 additional shares, and the company recently saw its stock jump after positive phase 3 clinical trial results and a significantly upsized secondary offering.
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target
Clear Street has initiated a "Buy" rating on Dianthus Therapeutics, Inc. (DNTH) and set a price target of $100. This indicates an optimistic outlook from the firm regarding Dianthus Therapeutics' future stock performance.
Dianthus Therapeutics (DNTH) Is Up 10.1% After $719M Raise And Insider Sale Has The Bull Case Changed?
Dianthus Therapeutics (DNTH) recently raised US$719 million through a public offering, and an executive sold shares under a Rule 10b5-1 plan. Despite the insider sale, favorable FDA trial updates and promising interim data for its lead therapies have led to reaffirmed positive analyst coverage. Investors are now evaluating how this significant capital raise impacts the company's investment outlook, given its focus on complement-focused pipeline and ongoing losses.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts
Dianthus Therapeutics (NASDAQ:DNTH) has received a consensus "Buy" recommendation from fourteen analysts, with an average 12-month price target of $115.55. Despite this, insiders, including CEO Marino Garcia, sold a significant number of shares in the last quarter. The company also reported weaker-than-expected quarterly earnings and has a negative P/E ratio, though institutional investors have been adjusting their positions.
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update
Dianthus Therapeutics' shares surged by 25% following an encouraging update from its clinical trial. The positive news appears to have significantly boosted investor confidence in the company.
[ARS] Dianthus Therapeutics, Inc. /DE/ SEC Filing
This article reports on Dianthus Therapeutics, Inc. (DNTH) filing an ARS form with the SEC on April 9, 2026. The filing is available as a PDF document and shows a neutral sentiment and low impact. The article also provides recent news and SEC filings for Dianthus Therapeutics, including information on its market cap and industry.
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH
SG Americas Securities LLC has invested $765,000 in Dianthus Therapeutics (NASDAQ:DNTH) by purchasing 18,565 shares in Q4. Despite this institutional buying and a "Buy" rating from analysts with an average price target of $115.55, Dianthus reported a significant EPS miss and negative net margins. Additionally, company insiders have sold a total of 323,021 shares worth $26.56 million in the last three months.
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares
Dianthus Therapeutics EVP Ryan Savitz sold 8,224 shares of the company's stock on April 9th for approximately $738,844. This transaction, executed under a pre-arranged Rule 10b5-1 plan, reduced his stake by 50% and follows a larger sale in March. Despite the insider selling and missed earnings estimates, Wall Street analysts maintain a "Buy" rating with an average price target of $115.55.
Dianthus Therapeutics Insider Sold Shares Worth $738,844, According to a Recent SEC Filing
An insider at Dianthus Therapeutics (DNTH) sold shares valued at $738,844, as reported in a recent SEC filing. This transaction follows other recent insider share sales and a public offering of common shares by the company. Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing antibody complement therapeutics for severe autoimmune diseases.
Dianthus (NASDAQ: DNTH) CFO exercises options, sells 8,224 shares under 10b5-1 plan
Dianthus Therapeutics' EVP, CFO & CBO, Ryan Savitz, exercised stock options for 8,224 shares at $17.88 per share and subsequently sold all 8,224 shares at a weighted average price of $89.84 per share. These transactions, valued at approximately $739,000, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025. Following the sale, Savitz holds 0 direct shares but retains 71,776 stock options.
Dianthus Therapeutics stock hits 52-week high at 90.2 USD
Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $90.19, reflecting a significant 436% return over the past year, despite InvestingPro analysis suggesting it is overvalued with a fair value of $55.16. This surge follows a successful public offering that raised $719 million and positive analyst ratings, with William Blair and Wells Fargo reiterating Outperform and Overweight ratings, respectively, after favorable FDA updates and promising clinical trial results for its drug claseprubart.
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Wolfe Research to "Strong-Buy" Rating
Dianthus Therapeutics (NASDAQ:DNTH) has been upgraded by Wolfe Research to a "strong-buy" rating, with multiple analysts also raising their price targets, resulting in a consensus "Buy" rating and an average price target of $115.55. Despite this positive analyst outlook, company insiders have been net sellers, with significant share disposals totaling $25.8 million over the last quarter. The stock's current trading price of $91.66 is near its 52-week high, reflecting recent gains following the news.
Ryan Savitz files Form 144 to sell 8,224 shares (NASDAQ: DNTH)
Ryan Savitz has filed a Form 144 to sell 8,224 shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) common stock, resulting from an option exercise on April 9, 2026, with an associated cash amount of $719,435.52. This filing also references previous 10b5-1 sales of 114,367 shares on March 31, 2026, which generated $9,492,532.35. The transaction involves Morgan Stanley Smith Barney LLC as the broker.
Dianthus Therapeutics stock hits 52-week high at 90.2 USD By Investing.com
Dianthus Therapeutics stock has reached a 52-week high of $90.19, reflecting a 436% one-year total return. Despite this surge, InvestingPro analysis suggests the stock is overvalued with a fair value of $55.16. The company recently completed a $719 million public offering and received positive analyst ratings following FDA updates and promising clinical trial results.
Wolfe Research initiates coverage of Dianthus Therapeutics (DNTH) with outperform recommendation
Wolfe Research has initiated coverage of Dianthus Therapeutics (DNTH) with an outperform recommendation. This indicates a positive outlook from the research firm regarding the company's stock performance.
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High - Time to Buy?
Dianthus Therapeutics (NASDAQ:DNTH) recently hit a new 52-week high of $89.72, with analysts generally rating it a "Moderate Buy" and having an average price target of $117.30. Despite this, the company reported an earnings per share miss of ($1.43) against an expected ($0.97) and has significant negative net margins. Furthermore, corporate insiders, including the CEO and EVP, have sold a substantial number of shares recently, though insiders still hold 16.56% and institutions 47.53% of the stock.
Dianthus Therapeutics, Inc. - Common Stock (DNTH) Stock Price, News, Quote & History
This page provides a comprehensive overview of Dianthus Therapeutics, Inc. (DNTH) stock, including its current price, market data, and recent news. Dianthus Therapeutics is a biopharmaceutical company specializing in innovative therapies for autoimmune diseases and cancer, utilizing antibody engineering. Recent news highlights include insider stock sales, public offerings to raise capital, and positive results from its Phase 3 CAPTIVATE trial for claseprubart.
DNTH SEC Filings - Dianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides access to Dianthus Therapeutics Inc. (DNTH) SEC filings, including 10-K, 10-Q, and 8-K reports, along with AI-powered summaries. Recent filings highlight a public offering of common stock and pre-funded warrants, positive Phase 2 trial data for claseprubart (DNTH103) in myasthenia gravis, and disclosures of significant stakes by institutional investors like Venrock-related entities, Point72, BCLS Fund III, and Vestal Point. The company is a clinical-stage biotechnology firm developing therapies for autoimmune and inflammatory diseases.
Dianthus Therapeutics Announces Inducement Grants
Dianthus Therapeutics, a Nasdaq-listed biotech company, has announced the issuance of inducement grants in the form of stock options to new employees. This move, common in the biotech industry, aims to attract and retain top talent to support the company's drug development pipeline and future growth. The grants were issued under Nasdaq Listing Rule 5635(c)(4) to offer competitive compensation packages to skilled professionals.
